

Patent claims

1. Medicament for tumor therapy during which a first and a second molecule are contained in an effective concentration,  
5 wherein the first molecule is

a1) Annexin V or a molecule which is largely similar thereto,

10 or

a2) an effective fragment of Annexin V or the molecule which is largely similar thereto,

15 and wherein the second molecule is

b1) a cytokine or a molecule which is largely similar thereto

20 or

b2) an effective fragment of a cytokine or the molecule which is largely similar thereto.

25 2. Medicament as defined in claim 1, wherein the amino acid sequence of the first molecule corresponds to the amino acid sequence of SEQ ID no. 1 or no. 2 or is identical thereto by at least 50%, preferably by at least 60%, particularly preferably by at least 70%, very particularly preferably by at  
30 least 80%.

3. Medicament as defined in one of the preceding claims, wherein the Annexin V is a non-human Annexin V.

35 4. Medicament as defined in one of the preceding claims, wherein the non-human Annexin V is the Annexin V of the chicken.

5. Medicament as defined in one of the preceding claims, wherein the cytokine is selected from the following group: Interleucine-2, Interleucine-6, Interleucine-7, Interleucine-12, GM-CSF, TNF- $\alpha$ , IL-1 $\beta$ .
6. Medicament as defined in one of the preceding claims, wherein 0.05 to 0.5 mg/g<sub>Tumorweight</sub> on the first molecule are contained in one unit of administration.
7. Medicament as defined in one of the preceding claims, wherein one unit of administration contains 0.1 to 2.5 mg, preferably 0.5 to 2.0 mg on the first molecule.
8. Medicament as defined in one of the preceding claims, wherein one unit of administration contains 50,000 to 1,000,000 International Units, preferably 300,000 to 750,000 International Units on the second molecule.
9. Medicament as defined in one of the preceding claims, wherein the first and the second molecule are held in an injection fluid, preferably in a buffered saline solution.
10. Medicament as defined in one of the preceding claims, wherein the volume of the injection fluid is 0.5 to 50 ml, preferably 1 to 10 ml.
11. Medicament as defined in one of the preceding claims, wherein it includes apoptotic and/or necrotic tumor cells.
12. Medicament as defined in one of the preceding claims, wherein it further includes human tumor cells.
13. Medicament as defined in one of the preceding claims, wherein the tumor cells are apoptotic and/or necrotic tumor cells of the tumor to be treated.

14. Medicament as defined in one of the preceding claims,  
wherein the tumor cells are in contact with the protein.

15. Use of a first molecule, namely

5

a1) Annexin V or a molecule which is largely similar thereto

or

10 a2) an effective fragment of Annexin V or the molecule which  
is largely similar thereto,

in combination with a second molecule, namely

15 b1) a cytokine or a molecule which is largely similar  
thereto

or

20 b2) an effective fragment of a cytokine or the molecule  
which is largely similar thereto,

for tumor therapy.

25 16. Use as defined in claim 15, wherein the tumor is a tumor  
effusion.

17. Use as defined in claim 15 or 16, wherein the tumor is a  
mamma carcinoma.

30

18. Use as defined in one of the claims 15 to 17, wherein  
the amino acid sequence of the first molecule corresponds to  
the amino acid sequence of SEQ ID no. 1 or no. 2, or is iden-  
tical thereto by at least 50%, preferably by at least 60%,

35 particularly preferably by at least 70%, very particularly  
preferably by at least 80%.

19. Use as defined in one of the claims 15 to 18, wherein the Annexin V is non-human Annexin V.

20. Use as defined in one of the claims 15 to 19 wherein the non-human Annexin V is the Annexin V of the chicken.

21. Use as defined in one of the claims 15 to 20, wherein the cytokine is selected from the following group: Interleucine-2, Interleucine-6, Interleucine-7, Interleucine-12, GM-CSF, TNF- $\alpha$ , IL-1 $\beta$ .

22. Use as defined in one of the claims 15 to 21, wherein one administration unit contains 0.05 to 0.5 mg/g<sub>tumorweight</sub> on the first molecule.

23. Use as defined in one of the claims 15 to 22, wherein one unit of administration contains 0.1 to 2.5 mg, preferably 0.5 to 2.0 mg on the first molecule.

24. Use as defined in one of the claims 15 to 23, wherein one unit of administration contains 50,000 to 1,000,000 International Units, preferably 300,000 to 750,000 International on the second molecule.

25. Use as defined in one of the claims 15 to 24, wherein the first and the second molecule are contained in an injection fluid, preferably in a buffered saline solution.

26. Use as defined in one of the claims 15 to 25, wherein the volume of the injection fluid is 0.5 to 50 ml, preferably 1 to 10 ml.

27. Use as defined in one of the claims 15 to 26, wherein it includes apoptotic and/or necrotic tumor cells.

28. Use as defined in one of the claims 15 to 27, wherein it further includes human tumor cells.

29. Use as defined in one of the claims 15 to 28, wherein  
5 the tumor cells are apoptotic and/or necrotic tumor cells of the tumor to be treated.

30. Use as defined in one of the claims 15 to 29, wherein the tumor cells are in contact with the protein.

10